Why the HAQ-II can be an effective substitute for the HAQ

F. Wolfe

Frederick Wolfe, M.D., Arthritis Research Center Foundation, University of Kansas School of Medicine, Wichita, Kansas, USA. Please address correspondence to:

Please address correspondence to: Frederick Wolfe, MD, National Data Bank for Rheumatic Diseases, Arthritis Research Center Foundation, 1035 N. Emporia, Suite 230, Wichita, KS 67214, USA. E-mail: fwolfe@arthritis-research.org Clin Exp Rheumatol 2005; 23 (Suppl. 39): S29-S30.

© Copyright Clinicaland Experimental Rheumatology 2005.

Key words: Database, data, outcomes, research, rheumatic diseases.

ABSTRACT

The HAQ-II is a psychometrically improved 10-item version of the stan-dard HAQ functional questionnaire. It is simpler and faster to administer and score, thereby reducing patient burden. HAQ-II is better correlated with clinical measures than the HAQ and is sensitive to change. The HAQ-II is suitable for use in the clinic and research studies.

Over several decades of use the Health Assessment Questionnaire (HAQ) (1) has demonstrated itself to be an extremely effective tool for measuring functional status and change in functional status in clinical trials and observational studies (2-5). However, use of the HAQ in the clinic has been distinctly uncommon (6). There are a number of reasons for this, including the apparent lack of relevance to clinicians and their unfamiliarity with the scale. However, the most important reason for lack of use appears to reside in the perceived difficulty in administration and scoring of the HAQ. Considering specific question and the use of aids and devices, the HAQ actually has 34 questions, including 20 items and 14 aids and devices, almost as many as the comprehensive SF-36 (7, 8). However, the HAQ collapses questions within categories so that the actual number of items used in scoring is 8.

Pincus proposed the Modified Health Assessment Questionnaire (MHAQ) in 1983 (9). He reduced the number of questions to 8 by choosing one question from each category. Although the MHAQ was used in a minority of clinical trials, it became apparent that it had a significant floor effect - too many values at 0 or too many patients with a normal function score. The MHAQ was then modified by adding two "difficult" questions, and the resultant questionnaire became the 10-item Multi-Dimensional Health Assessment Questionnaire (MDHAQ) (10). After this modification, the MDHAQ floor effect

was reduced. The MDHAQ had the additional advantage of being easier to score by virtue of its 10-item scale.

A number of problems became evident regarding the HAQ, MHAQ and MD-HAQ (11, 12). At the simplest level, the questionnaires had different mean scores in the same sample of patients, with the result that one could not compare results from a clinical trial that used one scale with the results from a trial that used a different scale. Besides incommensurability, it was never clear what scores constituted the easy-to-understand categories of mild, moderate and severe.

Several other problems were noted with HAQ, MHAQ and MDHAQ questionnaires that included "bad questions" or questions that were not understood clearly or answered accurately, or were answered differently by patients of different ages (12). Some such questions included "taking a tub bath," "shampoo your hair" or "participate in sports or games as you would like." These HAQ questionnaires also had distorted scaling properties. This can be understood analogously by comparing the scales with a 10 cm ruler in which the points on the scale do not fall at 1 cm difference points, but closer or farther away from the 1 cm difference in different areas of the ruler.

In 2004 we described the HAQ-II based on analyses conducted using the National Data Bank for Rheumatic Diseases (12). Using Rasch analysis (and confirmatory clinical knowledge), the shortened 10-item scale had no "bad items," excellent scaling properties (a good ruler), a reduced floor effect, and mean scores that were very similar to those of the HAQ, thus allowing comparison of group data using the HAQ and HAQ-II. The HAQ-II was at least as strongly, and often more strongly, correlated with clinical variables than the other HAQ scales (12). The HAQ-II questionnaire is shown in Figure 1. The general concordance of the two HAQ scales with the EuroQol




Fig. 1. The HAQ-II questionnaire. The 10-item questionnaire is simple to administer and score.




Fig. 2. Concordance of HAQ and HAQ-II with respect to the EuroQol quality of life utility scale.

utility is shown in Figure 2, indicating its overall concordance with the Euro-Qol (13).

Are there any practical differences between the scales? There are four central questions regarding scales for use in rheumatic disorders. Are they sensitive to change? Are they accurate measures? Are the scores comparable? Are they easy to use (low patient and physician burden)? A scale may be sensitive to change and yet not be a good measure. We have recently shown in a clinical trial that a VAS function scale was more sensitive to change than the

HAQ, HAQ-II and MDHAQ, but that the three HAQ scales performed similarly with regard to sensitivity to change (14). Although the HAQ-II is a "better" measurement scale, its superiority over the other scales is slight. In practical terms, then, any of the three scales will perform well. However, the scores of the HAQ and HAQ-II are similar, allowing the comparison of results between studies that use these two scales. Finally, the HAQ-II and MDHAQ are far easier to use in the clinic. These data suggest a primary role for the HAQ-II, as it has all of the four required qualities noted above.

References

- FRIES JF, SPITZ PW, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
- WOLFE F, PINCUS T, O'DELL J: Evaluation and documentation of rheumatoid arthritis disease status in the clinic: Which variables best predict change in therapy. *J Rheumatol* 2001; 28: 1712-7.
- WOLFE F:A reappraisal of HAQ disability in rheumatoid arthritis. *Arthritis Rheum* 2000; 43: 2751-61.
- BRUCE B, FRIESJF: The Stanford Health Assessment Questionnaire: A review of its history, issues, progress, and documentation. *J Rheumatol* 2003; 30: 167-78.
- WOLFE F, MICHAUD K, GEFELLER O, CHOI HK: Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1530-42.
- WOLFE F, PINCUS T, THOMPSON AK, DOYLE J: The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. *Arthritis Rheum* 2003; 49: 59-63.
- KELLER SD, MAJKUT TC, KOSINSKI M, WARE JE JR: Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: Overview. *Med Care* 1999; 37 (5 Suppl.): MS1-MS9.
- STEWART AL, HAYS RD, WARE JE: The MOS short-form general health survey. Med Care 1988: 26: 724-35.
- PINCUS T, SUMMEY JA, SORACI SA JR, WALLSTON KA, HUMMON NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-53.
- PINCUS T, SWEARINGEN C, WOLFE F: Toward a multidimensional Health Assessment
 Questionnaire (MDHAQ) Assessment of
 advanced activities of daily living and psychological status in the patient-friendly
 health assessment questionnaire format.

 Arthritis Rheum 1999; 42: 2220-30.
- 11. WOLFE F: Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8-item HAQ (DHAQ), and a rescored 20-item HAQ (HAQ20): Analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. *J Rheumatol* 2001; 28: 982-9.
- 12. WOLFE F, MICHAUD K, PINCUS T: Development and validation of the Health Assessment Questionnaire II: A revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004; 50: 3296-305.
- EUROQOL GROUP: EuroQol A new facility for the measurement of health-related quality of life. *Health Policy* 1990; 16: 199-208.
- 14. WOLFE F, MICHAUD K, PINCUS T, PANGAN AL, KENT J: Usefulness of a visual analog function scale in RAclinical trials: Increased sensitivity compared with conventional measures. Arthritis Rheum 2005; 50.